Babak Bamdad guides the Lincoln Hospital Pharmacy Department in New York as director and chief, and supervises all aspects of department operation. Active with the American Association of Pharmaceutical Scientists, Babak Bamdad has an extensive knowledge of new drugs on the market.
While Tamiflu has long been the most prevalent drug for annual flu shots, a new drug, Xofluza, was recently introduced. Both are marketed by Genentech and priced at around $150 wholesale, with Tamiflu also available in a generic version that costs about $50.
The first new flu drug to receive FDA approval in 20 years, Xofluza acts as an antiviral and usually works to reduce flu symptoms within a day. Common side effects include nausea, diarrhea, and headaches, with some pediatric patients also experiencing irritability and, in rare cases, seizures. The latter effects have caused some physicians to shy away from prescribing Xofluza to children, though the symptoms disappear once the medication is stopped.
Although Xofluza is described as safe, there is some concern in the medical community that it could lead to the formation of an adaptive superbug.
At Lincoln Medical and Mental Health Center, Babak Bamdad’s primary duties involve establishing and maintaining quality, performance, and productivity standards in accordance with those set by Presentation Medical Center.